BO 2367

Drug Profile

BO 2367

Alternative Names: (-) BO 2367

Latest Information Update: 19 May 2001

Price : $50

At a glance

  • Originator Banyu
  • Class Antineoplastics; Quinolones
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 May 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)
  • 23 Oct 1997 No-Development-Reported for Cancer in Japan (Unknown route)
  • 28 Nov 1996 Preclinical development for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top